Jon B Toledo1, Maria Bjerke1, Kewei Chen1, Martin Rozycki1, Clifford R Jack1, Michael W Weiner1, Steven E Arnold1, Eric M Reiman1, Christos Davatzikos1, Leslie M Shaw1, John Q Trojanowski2. 1. From the Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco. 2. From the Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco. trojanow@mail.med.upenn.edu.
Abstract
OBJECTIVE: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. METHODS: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. RESULTS: Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. CONCLUSIONS: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) pattern-based analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.
OBJECTIVE: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. METHODS: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. RESULTS: Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. CONCLUSIONS: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) pattern-based analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Jessica B Langbaum; Suzanne B Hendrix; Napatkamon Ayutyanont; Kewei Chen; Adam S Fleisher; Raj C Shah; Lisa L Barnes; David A Bennett; Pierre N Tariot; Eric M Reiman Journal: Alzheimers Dement Date: 2014-04-21 Impact factor: 21.566
Authors: Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust Journal: Ann Neurol Date: 2013-12 Impact factor: 10.422
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2013-08-07 Impact factor: 21.566
Authors: Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen Journal: JAMA Neurol Date: 2014-08 Impact factor: 18.302
Authors: Jon B Toledo; Steven E Arnold; Kevin Raible; Johannes Brettschneider; Sharon X Xie; Murray Grossman; Sarah E Monsell; Walter A Kukull; John Q Trojanowski Journal: Brain Date: 2013-07-10 Impact factor: 13.501
Authors: Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Jon B Toledo; Michael W Weiner; David A Wolk; Xiao Da; Kewei Chen; Steven E Arnold; William Jagust; Clifford Jack; Eric M Reiman; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski Journal: Acta Neuropathol Commun Date: 2014-03-06 Impact factor: 7.801
Authors: Xiao Da; Jon B Toledo; Jarcy Zee; David A Wolk; Sharon X Xie; Yangming Ou; Amanda Shacklett; Paraskevi Parmpi; Leslie Shaw; John Q Trojanowski; Christos Davatzikos Journal: Neuroimage Clin Date: 2013-11-28 Impact factor: 4.881
Authors: Mohamad Habes; Guray Erus; Jon B Toledo; Tianhao Zhang; Nick Bryan; Lenore J Launer; Yves Rosseel; Deborah Janowitz; Jimit Doshi; Sandra Van der Auwera; Bettina von Sarnowski; Katrin Hegenscheid; Norbert Hosten; Georg Homuth; Henry Völzke; Ulf Schminke; Wolfgang Hoffmann; Hans J Grabe; Christos Davatzikos Journal: Brain Date: 2016-02-24 Impact factor: 13.501
Authors: Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: José L Molinuevo; Laura A Rabin; Rebecca Amariglio; Rachel Buckley; Bruno Dubois; Kathryn A Ellis; Michael Ewers; Harald Hampel; Stefan Klöppel; Lorena Rami; Barry Reisberg; Andrew J Saykin; Sietske Sikkes; Colette M Smart; Beth E Snitz; Reisa Sperling; Wiesje M van der Flier; Michael Wagner; Frank Jessen Journal: Alzheimers Dement Date: 2016-11-05 Impact factor: 21.566
Authors: Daniel Ferreira; Farshad Falahati; Cecilia Linden; Rachel F Buckley; Kathryn A Ellis; Greg Savage; Victor L Villemagne; Christopher C Rowe; David Ames; Andrew Simmons; Eric Westman Journal: Sci Rep Date: 2017-03-13 Impact factor: 4.379
Authors: Argonde C van Harten; Michelle M Mielke; Dana M Swenson-Dravis; Clinton E Hagen; Kelly K Edwards; Rosebud O Roberts; Yonas E Geda; David S Knopman; Ronald C Petersen Journal: Neurology Date: 2018-06-29 Impact factor: 11.800